Momenta Pharmaceuticals Reports Second Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St mixed as benchmark Treasury yields reach 5%, oil takes a pause
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Goldman Sachs Downgrades Momenta Pharmaceuticals (MNTA) to Neutral
August 6, 2015 6:59 AM EDTGoldman Sachs downgraded Momenta Pharmaceuticals (NASDAQ: MNTA) from Buy to Neutral with a price target of $27 (unchanged).
For an analyst ratings summary and ratings history on Momenta Pharmaceuticals click here. For more ratings news on Momenta Pharmaceuticals click here.
Shares of Momenta Pharmaceuticals closed at $23.12 yesterday.
... MoreCowen Raises Price Target on Momenta Phama (MNTA) Following 2Q Results
August 5, 2015 9:57 AM EDTCowen reiterated a Market Perform rating on Momenta Pharmaceuticals (NASDAQ: MNTA), and raised the price target to $23.00 (from $18.00), following 2Q results. MNTA reported 2Q EPS of ($0.04) vs consensus of ($0.19).
Analyst Ritu Baral commented, "Investor focus remains Glatopa sales. Early launch looks... More
Momenta Pharmaceuticals (MNTA) PT Raised to $26 at Leerink Partners
August 5, 2015 7:58 AM EDTLeerink Partners analyst Jason Gerberry bumped his price target on Outperform-rated Momenta Pharmaceuticals (NASDAQ: MNTA) to $26.00 (from $25.00) following Q2 results.
Gerberry commented, "... MNTA reported better-than-expected top-line revenue of ~$45m vs our est of ~$7m driven by better-than-expected revenue recognition from Glatopa... More
